Efficacy of Vitamin E and Vitamin C in the Treatment of Nonalcoholic Steatohepatitis

INTRODUCTION Nonalcoholic steatohepatitis (NASH), a subset of nonalcoholic fatty liver disease (NAFLD), is becoming an increasing health concern, with current data showing the prevalence in the United States to range between 5.7%–16.5% (1,2). Patients with NASH lack a history of significant alcohol consumption, but liver biopsy findings are almost identical to biopsy findings in patients with alcoholic steatohepatitis (3,4). NASH is characterized by macrovesicular steatosis and hepatocyte injury with or without fibrosis (5,6). While NAFLD is generally considered to have a benign clinical course, NASH progresses to cirrhosis in 15%–25% of patients (2). Once cirrhosis develops, hepatocellular carcinoma may result. Furthermore, A SPECIAL ARTICLE